Most recently, the combination of durvalumab, an anti-PD-L1 ICI, and tremelimumab, an anti-CTLA-4 ICI, successfully completed a phase III trial in unresectable HCC and was approved for front-line use, with an mOS increase of 16.4 months [7]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.